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The UL144 open reading frame found in clinical isolates of
human CMV (HCMV) encodes a structural homologue of the
herpesvirus entry mediator, a member of the TNFR superfam-
ily. UL144 is a type I transmembrane glycoprotein that is ex-
pressed early after infection of ﬁbroblasts; however, it is re-
tained intracellularly. A YXXZ motif in the highly conserved
cytoplasmic tail contributes to UL144 subcellular distribution.
The ﬁnding that no known ligand of the TNF family binds
UL144 suggests that its mechanism of action is distinct from
other known viral immune evasion genes. Speciﬁc Abs to
UL144 can be detected in the serum of a subset of HCMV
seropositive individuals infected with HIV. This work estab-
lishes a novel molecular link between the TNF superfamily and
herpesvirus that may contribute to the ability of HCMV to
escape immune clearance. The Journal of Immunology, 1999,
162: 6967–6970.
R
ecent attention has focused on viral genes that target the
TNF-related cytokines and their cognate receptors, which
are crucial for effective cellular and humoral immune de-
fenses (1–3). Herpesviruses possess putative immune evasion
genes, each with a distinct mode of action targeting TNF super-
family. HSV-1 (a-herpesvirus), via envelope glycoprotein D, uti-
lizes as one of its routes of entry a member of the TNFR family,
the herpesvirus entry mediator (HVEM or HveA)
3 (4, 5). HVEM
is a receptor for the lymphotoxin (LT) ab-related ligand, LIGHT,
that also binds the LTbR (6), a critical receptor controlling orga-
nization of lymphoid tissue (7). Other examples include LMP-1
and v-FLIP in g-herpesviruses, proteins that act to modulate dis-
tinct TNFR signaling pathways (8, 9). We reasoned that these in-
timate links are not fortuitous, but rather are the result of speciﬁc
evolutionary history between TNF/LT cytokine systems and dif-
ferent species of herpesvirus. In this paper we provide evidence for
a novel molecular link between the TNF superfamily and a b-her-
pesvirus, human CMV (HCMV), in the form of a structural ho-
mologue of HVEM encoded by the UL144 ORF of HCMV.
Materials and Methods
Cell lines and viruses
293T cells and neonatal normal human dermal ﬁbroblasts (NHDF) (Clo-
netics, Walkersville, MD) were grown in DMEM (Life Technologies,
Gaithersburg, MD) supplemented with 10% FBS. HCMV-Fiala
(HCMV-F) is a low passage clinical isolate from a patient with AIDS and
was provided by M. Fiala (Department of Medicine, University of Cali-
fornia, Los Angeles). Other low passage isolates, ME, and LU, are from
solid organ transplant patients from Rush Clinical Labs (Rush-Presbyteri-
an-St. Lukes Medical Center, Chicago, IL).
UL144 constructs
HCMV-F DNA was isolated and used to amplify UL144 by PCR using
oligonucleotide primers of the HCMV strain Toledo (10) that contained 59
HindIII and 39 BamHI sites to facilitate subcloning into pCDNA3.1(1)
(Invitrogen, Carlsbad, CA). pUL144-myc was constructed by PCR ampli-
ﬁcation of the coding sequence of mature UL144 using oligonucleotide
primers to allow for addition of a 59 HindIII restriction site and a 39 BamHI
restriction site to facilitate ligation into pCDNA3.1(1) (Invitrogen). Se-
quences encoding the type I leader sequence of VCAM followed by the
c-myc epitope tag were PCR ampliﬁed from pLTbR-myc (11) with addi-
tion of a 59 NheI site and a 39 HindIII site and ligated immediately 59 of
UL144 in pCDNA3.1(1) to generate pUL144-myc. The cytoplasmic do-
main mutant of UL144 (pUL144YA-myc) was constructed by PCR-based
mutagenesis of pUL144-myc using a primer designed to introduce the
point mutation Y172A. PCR ampliﬁcations were performed using pfu
DNA polymerase (Stratagene, La Jolla, CA), and all vector sequences were
veriﬁed by dideoxynucleotide sequencing using an Applied Biosystems Prism
310 genetic analyzer (Perkin-Elmer, Foster City, CA). A fusion protein con-
sisting of the UL144-F ectodomain (aa 20-137) and a C-terminal human IgG1
Fc coding sequence (aa 231-447) (UL144:Fc) was constructed in pVL1393
(Invitrogen) for expression in baculovirus and puriﬁcation as described for
similar constructs (12). UL144:Fc was also constructed in PCR3 for expres-
sion in mammalian cells and puriﬁed as described (13). The anti-UL144:Fc
serum was produced in Sprague-Dawley rats by immunization with native and
SDS-denatured Fc fusion protein produced by insect cells. The serum was
absorbed with human IgG linked to agarose beads and showed no cross-
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c
creaction with other TNFR:Fc fusion proteins as determined by Western blot-
ting. Abs to IE1 (clone p63-27) and pp28 (clone 41-18) (14) were provided by
William Britt (University of Alabama, Birmingham).
Analysis of UL144 by FACS, Western blot analysis, and RT-PCR
293T cells (6 3 10
5) were seeded in a 6-well plate, and expression vectors
(5 mg) were transfected by the CaPO4 precipitation method as described
previously (15). Transfected 293T or virus-infected NHDF cells were de-
tached from plastic by treatment with 5 mM EDTA in PBS and resus-
pended in binding buffer (PBS, 2% FBS, and 0.02% sodium azide) for
staining. Cells were analyzed by a FACSCalibur (Becton Dickinson,
Mountain View, CA). Each histogram represents 10
4 viable cells gated on
forward and side-angle light scatter (6). For analysis by Western blot, cell
pellets were solubilized in SDS lysis buffer (1% SDS, 2 mM EDTA, 50
mM, Tris (pH 6.8), 1 mM PMSF, and 10 mg/ml aprotonin) and heated to
100°C for 10 min. Solubilized proteins were separated by SDS-PAGE and
transferred to a polyvinyidiene ﬂuoride membrane (NEN, Boston, MA).
Total cellular RNA from NHDF cells (3 3 10
6) infected with HCMV was
isolated using the RNeasy mini kit from Qiagen (Santa Clarita, CA). RNA
(1 mg) treated with one unit of DNase (Life Technologies) was reverse
transcribed (1 unit Superscript II; Life Technologies). The PCR utilized
UL144 forward primer, 59-gctgagcatgctattggcatgcatag-39 and reverse
primer, 59-gccgattgagcaacactgttggcatc-39; and ampliﬁcation at 94°C for 2
min followed by 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for
45 s (Perkin-Elmer 9600).
Assay to detect UL144-speciﬁc Abs in CMV seropositive patients
Serum samples obtained from the Center for AIDS Research (University of
California at San Diego) were heat-inactivated and assayed for HCMV
reactivity by latex agglutination “CMVscan” assay (Becton Dickinson).
Results and Discussion
Identiﬁcation of UL144 as an HVEM homologue
The second cysteine-rich domain (CRD) of HVEM containing the
TNFR signature sequence CLQCQMC was used as a query in a
BLAST search of the public database and identiﬁed UL144 ORF
in HCMV as an HVEM homologue. The UL144 ORF is located in
the unique long region of the HCMV genome, where 19 ORF were
recently discovered (10). These 19 putative genes are present only
in low passage, virulent strains of HCMV (originally identiﬁed in
Toledo), but not in several well-characterized laboratory strains of
HCMV (AD169 and Towne) (10).
The UL144 coding sequence was ampliﬁed by PCR from HCMV-
Fiala (UL144-F) genomic DNA. UL144-F encodes a type I trans-
membrane protein with an ectodomain comprised of a leader peptide,
cysteine-rich region, membrane extension region, transmembrane do-
main, and a short cytoplasmic tail (Fig. 1A). UL144-F differs from the
sequence of UL144-Toledo in 33 of 138 ectodomain residues (82%
identity at the nucleotide level). Sequence variation was also observed
in two other HCMV isolates (LU and ME) and in 28 other distinct
clinical HCMV isolates (N. S. Lurain et al, manuscript in preparation).
However, a high level of conservation is observed in all the isolates
including the number and positioning of the cysteines, as well as
complete identity in the transmembrane and cytoplasmic domains.
The eight putative N-linked glycosylation sites, located in CRD2 and
the membrane extension region, are conserved between all of the iso-
lates, except the Toledo variant which has seven. The UL144 ectodo-
main shows the highest amino acid sequence homology to HVEM
(36%) (Fig. 1B), followed by other members of the TNFR superfam-
ily (Fas, 29%; TNFR-1, 28%; LTbR, 25%; TRAIL-R2, 15%). UL144
encodes only two CRDs homologous to CRD1 and -2 of HVEM (4)
and is the ﬁrst identiﬁed member of the TNFR superfamily to be
comprised of only these two domains.
The CRD2 of UL144, while still showing highest homology to
HVEM (46% identity), displays signiﬁcant homology to the ligand
binding domain of TRAIL-R2 (43%) (16). Virtually all ligand-
receptor contacts present in the LTa/TNFR (55 kDa) complex oc-
cur in CRD2 and -3 (17), suggesting the possibility that UL144
may not possess a complete ligand binding domain. Furthermore,
in contrast to HVEM, which has a single putative glycosylation
site in CRD2, UL144 has six of its eight sites located in CRD2.
The UL144 ectodomain, when expressed in 293T cells as an Fc
fusion protein utilizing the IgG leader sequence, is highly glyco-
sylated (;20 kDa) as detected by digestion with endoglycosidase
F (Fig. 2). The extensive glycosylation of UL144:Fc indicates that
at least some of the eight predicted N-linked glycosylation sites are
modiﬁed in 293T cells. There was substantially less modiﬁcation
of the UL144:Fc protein produced in insect cells, but this is likely
FIGURE 1. Sequence homology of UL144 with TNFR superfamily. A, Multiple alignment of UL144 sequences (ClustalW, PAMseries, MacVector)
from Fiala (F), Toledo (T), and low passages isolates LU and ME. The outlined regions identify identical and conserved residues. The bars denote positions
of CRD1 and -2, and the transmembrane (tm) and cytoplasmic (cyto) domains. B, Pairwise alignment of CRD1 and -2 of HVEM and UL144-F. Boxed
regions show identity and conservative substitutions, and p denotes N-linked glycosylation sites. The GenBank accession numbers are AF135184 for
UL144-F and U33331 for Toledo.
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drates seen in this cell type. The extensive homology of the UL144
ectodomain with HVEM and TNFR family members prompted
us-to screen for binding to TNF-related ligands. Using a sensitive
ELISA method, none of the ligands, including TRAIL, LIGHT,
LTa,L T a1b2, TNF, FasL, CD40L, CD30L, Tweak, 41BBL,
OX40L, April, RankL, or TL1 bound to UL144:Fc, whether the
fusion protein was produced in insect or mammalian cells. Addi-
tionally, unlike HVEM, UL144 does not appear to serve as an entry
factor for HSV-1 (C. A. Benedict, S. Borboroglu, and C. F. Ware,
unpublished observations). Thus, the ability of UL144 to function as
a ligand binding molecule appears unlikely, perhaps due to extensive
glycosylation, although we cannot exclude interactions with a yet un-
characterized ligand. Furthermore, unlike cellular TNFR, UL144 does
not appear to induce apoptosis or modulate activation of NF-kB when
over-expressed.
Expression of UL144 in HCMV infected cells
None of the putative 19 ORF in clinical HCMV isolates have been
shown to be expressed during a viral infection. RT-PCR analysis
of RNA from NHDF showed UL144-speciﬁc transcripts in cells
infected with HCMV-F but not AD169 (Fig. 3A) (AD169 lacks the
genomic locus containing UL144) (10). UL144 protein was also
detected in HCMV-F-infected ﬁbroblasts by Western blot analysis
with anti-UL144:Fc serum as a major band of ;44 kDa and a
minor 38-kDa component (Fig. 3B). In agreement with the en-
doglycosidase F digestion, extensive posttranslational modiﬁca-
tion of UL144 probably occurs to account for the difference in the
predicted mass of 19.4 kDa. UL144 protein is expressed early (4 h)
after infection, as early as the immediate early protein-1 (IE1) of
HCMV, in contrast to the expression of pp28, a late protein that is
not detectable until ;48–72 h postinfection (Fig. 3B) (18).
Surprisingly, anti-UL144 did not stain infected ﬁbroblasts by
FACS (Fig. 3C), although UL144 protein was readily detected by
Western blot analysis (Fig. 3B), and this antiserum was fully ca-
pable of staining of 293T cells transfected with a UL144 expres-
sion vector (pUL144YA-myc; see below) (Fig. 3C). Furthermore,
no shed or secreted UL144 was detected in the supernatant from
infected cells (data not shown). Together, these results indicate
that UL144 is retained in an intracellular compartment. The anti-
UL144 did not block HCMV infectivity; however, this result does
not preclude UL144 as a component of the virion.
The YRTL sequence in the conserved cytoplasmic tail of UL144
resembles a YXXZ motif (Z is a bulky hydrophobic amino acid),
a motif important in sorting of some transmembrane proteins, and
thus may be involved in regulating UL144 subcellular distribution.
YXXZ motifs can interact directly with the adaptor complexes
associated with clathrin-mediated receptor internalization at the
plasma membrane and in the trans-Golgi network (19). A Tyr to
Ala mutant of UL144 (pUL144YA-myc), when over-expressed in
293T cells, was displayed at signiﬁcantly higher levels (7- to 10-
fold) on the cell surface than the wild-type UL144 protein, al-
though total cellular protein levels were equivalent (Fig. 3, C and
D). Additionally, endoglycosidase H treatment of UL144YA pro-
tein immunoprecipitated from 293T cell lysates revealed a distinct
banding pattern from that of UL144 (data not shown). Together,
these data suggest that the sorting of UL144 is controlled in part by
the YRTL sequence and is the ﬁrst identiﬁcation of such a motif in
FIGURE 2. Glycosylation of UL144. UL144:Fc protein (5 mg) puriﬁed
from either 293T or insect cells infected with recombinant baculovirus
(BV) was digested with endoglycosidase F (EndoF; 37°C for 60 min) for
analysis of N-linked glycosylation. The gel was stained with Coomassie
blue for detection of proteins.
FIGURE 3. Expression of UL144 during viral infection. A, RT-PCR to
detect UL144 expression. NHDF cells were either mock infected, infected
with AD169 or HCMV-F, and cells were harvested 72 h postinfection (pi) for
extraction of total cell RNA. Total cell RNA (1 mg) was used for the reverse
transcription (RT) reaction. RT negative reactions (RT2) were treated exactly
the same, but enzyme was omitted from the RT reaction step. The RT reaction
(1/12th) was used for PCR ampliﬁcation of either UL144 or b-actin; 1, pos-
itive control as UL144 cDNA (10 ng of pUL144-myc). B, HCMV-F or
AD169-infected NHDF cells were analyzed at various times for expression of
UL144 protein. UL144 protein was detected with anti-UL144:Fc (1:500) fol-
lowed by incubation with sheep anti-rat IgG Ab conjugated to HRP and en-
hanced chemiluminescence. C, Detection of cell surface UL144 by FACS.
NHDF cells (top panel), mock infected or infected with HCMV-F (moi 5 5),
were stained with rat anti-UL144 or preimmune (PI) serum (1:200) followed
by goat F(ab9)2 anti-rat R-PE-conjugated Ab. 293T cells (bottom panel) trans-
fected with empty vector or or pUL144YA-myc were stained by rat anti-
UL144 as described above. D, 293T cells were transfected with either
pUL144-myc or pUL144YA-myc, and protein levels were detected by FACS.
Inset, Western blot comparing total cellular protein levels of cells transfected
with UL144 (lane 1), UL144YA (lane 2), or vector only (lane 3). For FACS,
cell surface protein was detected with anti-myc Ab (9E10, 25 mg/ml) followed
by incubation with goat F(ab9)2 anti-mouse R-PE-conjugated Ab. For Western
blots, equivalent amounts of total protein were analyzed by SDS-PAGE, and
blots were incubated with 9E10 (10 mg/ml) followed by sheep anti-mouse IgG
HRP conjugated Ab.
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dicates that multiple regions, particularly the N-terminal region,
may also contribute to expression and subcellular compartmental-
ization of UL144.
Detection of speciﬁc Abs to UL144 in HCMV seropositive patients
We looked for evidence of UL144 expression during the course of
a viral infection in vivo by serologic detection of speciﬁc UL144
Abs. The higher cell surface levels of the UL144YA mutant ex-
pressed by 293T cells made possible a FACS-based assay for de-
tection of UL144 Abs. As CMV can be an opportunistic pathogen
in AIDS patients, sera from a HIV-positive cohort were investi-
gated. Two groups with either high or low Abs binding levels to
UL144 were identiﬁed in CMV-positive patients (n 5 25) (Fig. 4).
These sera were negative on nontransfected cells, and serum from
CMV seronegative patients did not stain 293T cells expressing
UL144YA protein. These results substantiate the speciﬁcity of this
assay for UL144. Clinical status or antiviral therapy may contrib-
ute to waning Ab levels in some patients. Alternatively, variation
in reactivity may depend on speciﬁc serologic reaction with dif-
ferent UL144 variants. This latter possibility is supported by the
sequence diversity observed in the ectodomain of UL144 (Fig.
1B). These issues are currently being addressed.
This ﬁrst identiﬁcation of a TNFR family member encoded by a
b-herpesvirus may be helpful in unraveling the mechanisms in-
volved in the ability of HCMV to escape immune clearance. The
inability of UL144 to bind any of the currently identiﬁed TNF
family ligands or induce signaling events akin to known TNFR
suggests its action will be intracellular and differ from other known
immune evasion strategies. The intracellular localization of UL144
is reminiscent of the poxvirus T2 protein, a TNFR homologue,
which functions biologically as a host range restriction factor to
allow for productive viral replication in lymphocytes (20). Al-
though we see no evidence for a blockade of apoptosis, it is pos-
sible that UL144 may be functioning in a similar fashion in other
cell types, and this hypothesis is currently under investigation. The
results presented here help establish the relevance of UL144 to the
immune response and should provide additional impetus to inves-
tigate this new target, as well as the additional genes at the newly
described region, with the hope to unravel this pathogen’s well-
guarded secrets of immune evasion.
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FIGURE 4. Abs to UL144 exist in human serum from HCMV seropos-
itive individuals. Human serum from 25 HCMV seropositive patients and
3 seronegative patients (including three serial samples from one patient)
were tested for Ab reactivity against the UL144 ectodomain. Upper panel,
Representative histograms from FACS analysis of human anti-UL144 Ab
reactivity. Patient serum samples were diluted 1:50 and incubated with
293T cells transfected with pUL144YA-myc or with vector. Ab binding
was detected with goat anti-human IgG F(ab9)2 conjugated to R-PE. Lower
panel, Fluorescence intensity (FI, mean peak ﬂuorescence channel) for all
tested human serum samples reactivity against UL144. FI was calculated
by subtracting FI for Ab binding to vector transfected 293T cells from
UL144YA-transfected 293T cells.
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